z-logo
open-access-imgOpen Access
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Author(s) -
Donia M. Moujalled,
Fiona C. Brown,
Chong Chyn Chua,
Michael A. Dengler,
Giovanna Pomilio,
Natasha S. Anstee,
Véronique Litalien,
Ella R. Thompson,
Thomas Morley,
Sarah MacRaild,
Ing Soo Tiong,
Rhian Morris,
Karen Dun,
Adrian Zordan,
Jaynish S. Shah,
Sébastien Banquet,
Ensar Halilovic,
Erick J. Morris,
Marco J. Herold,
Guillaume Lessène,
Jerry M. Adams,
David C.S. Huang,
Andrew W. Roberts,
Piers Blombery,
Andrew H. Wei
Publication year - 2022
Publication title -
blood
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2022016090
Subject(s) - venetoclax , myeloid leukemia , azacitidine , leukemia , cancer research , chemotherapy , medicine , cytarabine , myeloid , immunology , biology , dna methylation , gene , chronic lymphocytic leukemia , genetics , gene expression

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom